BIOR 1.90 Stock Price Biora Therapeutics, Inc.
Range: | 1.43-19.9 | Vol Avg: | 65469 | Last Div: | 0 | Changes: | 0.04 |
Beta: | 1.28 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Fri Jun 19 2020 | Empoloyees: | 58 |
CUSIP: | 74319F107 | CIK: | 0001580063 | ISIN: | US74319F3055 | Country: | US |
CEO: | Mr. Aditya P. Mohanty M.B.A. | Website: | https://www.bioratherapeutics.com |
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.